LONDON, UK/ROTTERDAM, Netherlands: Unilever has announced that it has signed an agreement to acquire the Fluocaril and Parogencyl oral care brands from Procter & Gamble.
Fluocaril and Parogencyl are well-known therapeutic brands sold in the pharmaceutical industry, primarily in France and Spain. They have a product portfolio that is widely endorsed by health professionals. Fluocaril offers oral care solutions specialising in protection against dental caries. Parogencyl tackles gingival issues.
The acquisition will give Unilever a leading role in oral care in the pharmaceutical industry in France, as well as a strong position in Spain. With their powerful brand heritage, high visibility and sound reputation with dentists, these brands are a great complement to the existing oral care portfolio of Unilever.
The terms of the deal were not disclosed. The acquisition is expected to close in the second quarter of 2019.